⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Phosphoric Acid SCHEMBL11024761 | 0.91 | EGLN1 (0.48) | — | |
| Phosphonic Acid SCHEMBL11027764 | 0.91 | EGLN1 (0.48) | — | |
| SCHEMBL6916161 | 0.81 | ALDH1A1 (0.46) | — | |
| SCHEMBL23988162 | 0.80 | EGLN1 (0.52) | — | |
| SCHEMBL7225123 | 0.79 | — | — | |
| SCHEMBL1653979 | 0.77 | — | — | |
| SCHEMBL2701001 | 0.77 | — | — | |
| SCHEMBL12495312 | 0.77 | EGLN1 (0.65) | — | |
| SCHEMBL923438 | 0.77 | EGLN1 (0.65) | — | |
| SCHEMBL13589411 | 0.77 | EGLN1 (0.65) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 98 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0271443-B1 | N,N'-DISUBSTITUTED UREAS AND PROCESS FOR THEIR PRODUCTION | CIBA-GEIGY AG (CH) | 1990-10-17 | — | — | EP | claimed |
| US-12370158-B2 | Analogs of CYP-eicosanoids for use in treating or preventing a disorder associated with neovascularization and/or inflammation | OMEICOS THERAPEUTICS GMBH (DE) | 2025-07-29 | — | — | US | disclosed |
| CN-119367342-A | CYP-eicosanoids analogs for treating or preventing diseases associated with neovascularization and/or inflammation | 奥迈科斯治疗公司 | 2025-01-28 | — | — | CN | disclosed |
| EP-3435993-B1 | ANALOG OF CYP-EICOSANOIDS FOR USE IN TREATING OR PREVENTING A DISORDER ASSOCIATED WITH NEOVASCULARIZATION AND/OR INFLAMMATION | OMEICOS THERAPEUTICS GMBH (DE) | 2024-09-25 | — | — | EP | disclosed |
| CN-117580831-A | GRK2 inhibitors and uses thereof | 索纳塔治疗公司 | 2024-02-20 | — | — | CN | disclosed |
| US-11718612-B2 | Inhibitors of receptor interacting protein kinase I for the treatment of disease | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2023-08-08 | — | — | US | disclosed |
| US-11691992-B2 | Oxaborole analogs and uses thereof | ANACOR PHARMACEUTICALS, INC. (US) | 2023-07-04 | — | — | US | disclosed |
| EP-4196220-A1 | TRIAZOLE-PYRIDINYL SUBSTITUTED AZACYCLOHEXYL ACETIC ACID COMPOUNDS AS LPA RECEPTOR ANTAGONISTS | Viva Star Biosciences Limited (HK) | 2023-06-21 | — | — | EP | disclosed |
| EP-3313816-B1 | METABOLICALLY ROBUST ANALOGS OF CYP-EICOSANOIDS FOR THE TREATMENT OF CARDIAC DISEASE | OMEICOS THERAPEUTICS GMBH (DE) | 2023-05-24 | — | — | EP | disclosed |
| EP-3313816-B1 | METABOLICALLY ROBUST ANALOGS OF CYP-EICOSANOIDS FOR THE TREATMENT OF CARDIAC DISEASE | OMEICOS THERAPEUTICS GMBH (DE) | 2023-05-24 | — | — | EP | disclosed |
| US-20070105855-A1 | NOVEL HETEROCYCLIC COMPOUNDS USEFUL FOR THE TREATMENT OF INFLAMMATORY AND ALLERGIC DISORDERS: PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | GLENMARK PHARMACEUTICALS S.A. (CH) | 2007-05-10 | — | — | US | disclosed |
| US-7173029-B2 | Fused heteroaryl derivatives | ASTELLAS PHARMA INC. (JP) | 2007-02-06 | — | — | US | disclosed |
| US-7173029-B2 | Fused heteroaryl derivatives | ASTELLAS PHARMA INC. (JP) | 2007-02-06 | — | — | US | disclosed |
| WO-2004089940-A1 | NOVEL HETEROCYCLIC COMPOUNDS USEFUL FOR THE TREATMENT OF INFLAMMATORY AND ALLERGIC DISORDERS: PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | GLENMARK PHARMACEUTICALS S.A. (US) | 2004-10-21 | — | — | WO | disclosed |
| US-6316482-B1 | FOR THERAPY AND PROPHYLAXIS OF HYPERTENSION, HEART FAILURE, RENAL INSUFFICIENCY, EDEMA, ASCITES, VASOPRESSIN PARASECRETION SYNDROME, HEPATOCIRRHOSIS, HYPONATREMIA, HYPOKALEMIA, DIABETIC, CIRCULATION DISORDER, CEREBROVASCULAR DISEASE | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2001-11-13 | — | — | US | disclosed |
| US-6207693-B1 | Benzamide derivatives having a vasopressin antagonistic activity | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2001-03-27 | — | — | US | disclosed |
| EP-0946519-A1 | BENZAMIDE DERIVATIVES HAVING A VASOPRESSIN ANTAGONISTIC ACTIVITY | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1999-10-06 | — | — | EP | disclosed |
| WO-1998024771-A1 | BENZAMIDE DERIVATIVES HAVING A VASOPRESSIN ANTAGONISTIC ACTIVITY | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1998-06-11 | — | — | WO | disclosed |
| EP-0696272-A1 | CYCLOOXYGENASE AND 5-LIPOXYGENASE INHIBITING N(3-BIPHENYLYL-1(S)-METHYL-2-PROPENYL) ACETOHYDROXAMIC ACID DERIVATIVES | THE WELLCOME FOUNDATION LIMITED (GB) | 1996-02-14 | — | — | EP | disclosed |
| WO-1994025431-A1 | CYCLOOXYGENASE AND 5-LIPOXYGENASE INHIBITING N(3-BIPHENYLYL-1(S)-METHYL-2-PROPENYL) ACETOHYDROXAMIC ACID DERIVATIVES | THE WELLCOME FOUNDATION LIMITED (GB) | 1994-11-10 | — | — | WO | disclosed |